View:
Download DOC
Download PDF
Download XLS
Download XBRL
false 0000001800 Common Shares, Without Par Value ABT 0000001800 2024-04-26 2024-04-26 0000001800 us-gaap:CommonStockMember exch:XCHI 2024-04-26 2024-04-26 0000001800 us-gaap:CommonStockMember exch:XNYS 2024-04-26 2024-04-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
   

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

April 26, 2024

Date of Report (Date of earliest event reported)

  

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

 

Illinois   1-2189   36-0698440
(State or other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading
Symbol(s)

Name of Each Exchange
 on Which Registered

Common Shares, Without Par Value ABT New York Stock Exchange
 Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.07 — Submission of Matters to a Vote of Security Holders.

 

Abbott held its Annual Meeting of Shareholders on April 26, 2024. The following is a summary of the matters voted on at that meeting.

 

(1)The shareholders elected Abbott’s entire Board of Directors. The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number against, the number abstaining, and the number of broker non-votes, with respect to each of these persons, were as follows:

 

Name  Votes For   Votes Against   Abstain   Broker Non-Votes 
Robert J. Alpern, M.D.   1,313,710,177    44,337,309    2,622,282    177,819,859 
Claire Babineaux-Fontenot   1,349,829,767    8,983,741    1,856,260    177,819,859 
Sally E. Blount, Ph.D.   1,325,092,846    32,959,734    2,617,188    177,819,859 
Robert B. Ford   1,264,303,130    90,184,905    6,181,733    177,819,859 
Paola Gonzalez   1,345,099,739    13,054,211    2,515,818    177,819,859 
Michelle A. Kumbier   1,341,455,910    16,651,339    2,562,519    177,819,859 
Darren W. McDew   1,340,191,689    17,894,587    2,583,492    177,819,859 
Nancy McKinstry   1,115,514,137    242,620,096    2,535,535    177,819,859 
Michael G. O’Grady   1,337,188,483    20,824,225    2,657,060    177,819,859 
Michael F. Roman   1,324,846,657    32,483,527    3,339,584    177,819,859 
Daniel J. Starks   1,318,741,720    39,288,121    2,639,927    177,819,859 
John G. Stratton   1,010,774,107    347,305,245    2,590,416    177,819,859 

 

(2)The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For  Against   Abstain   Broker Non-Votes 
1,492,386,144   42,865,598    3,237,885    0 

 

(3)The shareholders approved the compensation of Abbott’s named executive officers listed in the proxy statement for the Annual Meeting, with 89.10 percent of the votes cast voting “For” the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For  Against   Abstain   Broker Non-Votes 
1,212,361,360   144,228,907    4,079,501    177,819,859 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBOTT LABORATORIES
   
Date: April 29, 2024 By: /s/ Philip P. Boudreau
    Philip P. Boudreau
    Senior Vice President, Finance and Chief Financial Officer